Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report

Abstract Hyperprogressive disease (HPD) is a novel progressive pattern that occurs after immune checkpoint inhibitor (ICI) administration. Here, a 74‐year‐old woman who had undergone right lower lobectomy for lung cancer received curative chemoradiotherapy followed by consolidation therapy with durv...

Full description

Bibliographic Details
Published in:	Thoracic Cancer
Main Authors:	Kosuke Masuda, Yoshiaki Nagai, Hikari Amari, Hiroki Tahara, Yuki Maeda, Jun Shiihara, Hiromitsu Ohta, Masahiro Hiruta, Yasuhiro Yamaguchi
Format:	Article
Language:	English
Published:	Wiley 2023-11-01
Subjects:	hyperprogressive disease immune checkpoint inhibitor lung cancer
Online Access:	https://doi.org/10.1111/1759-7714.15104

Similar Items

Hyperprogression: A novel response pattern under immunotherapy
by: Xue‐jiao Han, et al.
Published: (2020-09-01)

Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
by: Marta Brambilla, et al.
Published: (2020-12-01)

Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature
by: Jan Skacel, et al.
Published: (2023-12-01)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
by: Zhanqi Wei, et al.
Published: (2022-05-01)

Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer
by: Jie Zhou, et al.
Published: (2025-04-01)

A Case of Lung Cancer Exhibiting Pleoymorphic Carcinoma Transformation Resistance Following Treatment With Osimertinib That Was Successfully Treated Using Local Ablative Treatment
by: Yoshiaki Nagai, et al.
Published: (2025-01-01)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
by: Yong Jun Choi, et al.
Published: (2020-10-01)

Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?
by: Alkader Mohammad S., et al.
Published: (2024-03-01)

Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review
by: Kang-Xin Wang, et al.
Published: (2025-03-01)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
by: Romain Varnier, et al.
Published: (2021-09-01)

Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
by: Caner Acar, et al.
Published: (2024-10-01)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
by: Shiyun Chen, et al.
Published: (2023-08-01)

Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition
by: Yikun Li, et al.
Published: (2024-12-01)

Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis
by: Bo Pei, et al.
Published: (2024-09-01)

First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review
by: Ya-Zhou Wang, et al.
Published: (2024-10-01)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
by: Daniela R. Montagna, et al.
Published: (2022-08-01)

Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease
by: Daria Kravchuk, et al.
Published: (2025-02-01)

Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
by: Yan Chen, et al.
Published: (2020-07-01)

Risk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion
by: Yiyue Huang, et al.
Published: (2024-11-01)

Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
by: Yaping Long, et al.
Published: (2023-09-01)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
by: Zijun Zhao, et al.
Published: (2022-08-01)

Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report
by: Yao Zhang, et al.
Published: (2024-12-01)

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Wang X, et al.
Published: (2023-01-01)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
by: Yanping Li, et al.
Published: (2023-05-01)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
by: Rui Zhou, et al.
Published: (2023-11-01)

Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
by: Jun Shiihara, et al.
Published: (2021-09-01)

Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature
by: Guangjian Yang, et al.
Published: (2025-01-01)

Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review
by: Jiajie He, et al.
Published: (2023-11-01)

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
by: Stefania Angelicola, et al.
Published: (2025-01-01)

Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
by: Huijie Zhou, et al.
Published: (2023-03-01)

Advances of the Correlation between Driver Gene Status and Immunotherapy  in Non-small Cell Lung Cancer
by: Jie CHEN, et al.
Published: (2019-04-01)

A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice
by: Guo Hanfei, et al.
Published: (2021-12-01)

Case report: Molecular characterization of adult atypical teratoid rhabdoid tumor and review of the literature
by: Miguel A. Hernandez-Rovira, et al.
Published: (2025-02-01)

Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients
by: Francesca Romana Di Pietro, et al.
Published: (2024-08-01)

Advanced Merkel cell carcinoma in setting of pembrolizumab therapy for squamous cell carcinoma
by: Henry Jeon, BSc, et al.
Published: (2024-05-01)

MDM2 inhibitors in cancer immunotherapy: Current status and perspective
by: Qinru Zeng, et al.
Published: (2024-11-01)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Andrea Alberti, et al.
Published: (2022-06-01)

Steroid resistance in organizing pneumonia caused by pulmonary cryptococcosis
by: Motoko Nomura, et al.
Published: (2020-05-01)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
by: Yuhei Kinehara, MD, PhD, et al.
Published: (2023-11-01)